Skip to main content

Animations

MJFF Publications

5361 - 5370 of 8606 Results
Title
Year
  • Year
  • 2024
  • 2025
  • 2013
  • 2019
  • 2014
  • 2024
  • 2018
  • 2019
  • 2015
  • 2020
  • Summary Details
    OPEN
    Title: Genetic and pharmacological reduction of CDK14 mitigates synucleinopathy
    Journal Name: Cell Death & Disease
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1038/s41419-024-06534-8
    Citation Count: 5
  • Summary Details
    OPEN
    Title: Current safety recommendations for handling mouse and human αsynuclein pre-formed fibrils
    Journal Name: Neurobiology of Disease
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1016/j.nbd.2025.106820
    Citation Count: 0
  • Summary Details
    RESTRICTED
    Title: Improvement of freezing of gait with amantadine in a patient with oculopharyngeal muscular dystrophy and parkinsonism
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2013.02.016
    Best OA location URL:
    Citation Count: 0
  • Summary Details
    OPEN
    Title: Spring is in the air: seasonal profiles indicate vernal change of miRNA activity
    Journal Name: RNA Biology
    Publisher: Informa UK Limited
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1080/15476286.2019.1612217
    Citation Count: 14
  • Summary Details
    OPEN
    Title: IntranasalNAP(davunetide) decreases tau hyperphosphorylation and moderately improves behavioral deficits in mice overexpressing α‐synuclein
    Journal Name: Pharmacology Research & Perspectives
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1002/prp2.65
    Best OA location URL: https://doi.org/10.1002/prp2.65
    Citation Count: 43
  • Summary Details
    OPEN
    Title: Leveraging sex-genetic interactions to understand brain disorders: recent advances and current gaps
    Journal Name: Brain Communications
    Publisher: Oxford University Press (OUP)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1093/braincomms/fcae192
    Citation Count: 0
  • Summary Details
    RESTRICTED
    Title: Validation of the MDS clinical diagnostic criteria for Parkinson's disease
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1002/mds.27362
    Best OA location URL:
    Citation Count: 241
  • Summary Details
    OPEN
    Title: Development of a Disease Progression Model for Leucine‐Rich Repeat Kinase 2 in Parkinson's Disease to Inform Clinical Trial Designs
    Journal Name: Clinical Pharmacology & Therapeutics
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/cpt.1634
    Citation Count: 18
  • Summary Details
    OPEN
    Title: Visual Hallucinations in Eye Disease and Lewy Body Disease
    Journal Name: The American Journal of Geriatric Psychiatry
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.jagp.2015.10.007
    Citation Count: 28
  • Summary Details
    OPEN
    Title: Wrinkle in the plan: miR-34a-5p impacts chemokine signaling by modulating CXCL10/CXCL11/CXCR3-axis in CD4+, CD8+T cells, and M1 macrophages
    Journal Name: Journal for ImmunoTherapy of Cancer
    Publisher: BMJ
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.1136/jitc-2020-001617
    Citation Count: 42
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.